IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome
on behalf of the TAIDI (Toulouse Acquired Immune Deficiency and Infection) study group, E. Dufranc, Arnaud Del Bello, Julie Bellière, Nassim Kamar, Stanislas Faguer
Abstract
International audience
Topics & Concepts
MedicineTocilizumabCritically illBlocking (statistics)Critical illnessHemophagocytic lymphohistiocytosisIntensive care medicineCoronavirus disease 2019 (COVID-19)Systemic inflammatory response syndromeSepsisInternal medicineMathematicsStatisticsDiseaseInfectious disease (medical specialty)Autoimmune and Inflammatory Disorders ResearchChildhood Cancer Survivors' Quality of LifeAdolescent and Pediatric Healthcare